|
"Generic Erbitux for Treatment of EGFR+ Cancer."
|
N44CO120044-000
|
$2,479,561
|
$2,479,561
|
HU, PEISHENG
|
CANCER THERAPEUTICS LABORATORY INC
|
|
15-LOX-1 effects on colitis and colon cancer
|
5R01CA137213-04
|
$309,964
|
$309,964
|
SHUREIQI, IMAD
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
2-Amino-9H-pyrido[2,3-b]indole: a potential colorectal carcinogen formed in tobac
|
5R01CA134700-03
|
$327,269
|
$327,269
|
Turesky, Robert
|
WADSWORTH CENTER
|
|
4D Robust Optimization in Intensity-Modulated Proton Therapy
|
1K25CA168984-01
|
$125,174
|
$62,587
|
Liu, Wei
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
A 3-D in vitro platform of tumor metastasis (PQ24)
|
1R01CA170879-01
|
$338,175
|
$338,175
|
GEORGE, STEVEN
|
UNIVERSITY OF CALIFORNIA IRVINE
|
|
A Cancer Rainbow Mouse for the Simultaneous Assessment of Multiple Oncogenes
|
1R21CA173245-01
|
$235,546
|
$77,730
|
Caron, Marc
|
DUKE UNIVERSITY
|
|
A Cellular and Molecular Analysis of the Intravasation Step in Tumor Metastasis
|
5R01CA129484-05
|
$381,417
|
$190,709
|
QUIGLEY, JAMES
|
SCRIPPS RESEARCH INSTITUTE
|
|
A Center for the Convergence of Physical Science and Cancer Biology
|
5U54CA143862-04
|
$1,680,677
|
$1,680,677
|
Davies, Paul
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
A Drosophila Model Linking Diet-induced Obesity and Cancer (PQ 1)
|
1R01CA170495-01
|
$351,713
|
$351,713
|
Cagan, Ross
|
MOUNT SINAI SCHOOL OF MEDICINE
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
1UM1CA164974-01A1
|
$2,196,670
|
$439,334
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A Follow-up Study for Causes of Illness in Black Women
|
5R01CA058420-19
|
$1,716,455
|
$858,228
|
Rosenberg, Lynn
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A Genetic Model for Early-Onset Breast and Colon Cancer in African Americans
|
1U01CA158428-01A1
|
$342,475
|
$171,238
|
Buckhaults, Phillip
|
GEORGIA HEALTH SCIENCES UNIVERSITY
|
|
A Genetic Screen for HCC Genes
|
5R01CA132962-03
|
$302,919
|
$302,919
|
LARGAESPADA, DAVID
|
UNIVERSITY OF MINNESOTA
|
|
A Model for Preclinical Biomarker Discovery in Pancreatic Ductal Adenocarcinoma
|
5K08CA137153-03
|
$163,080
|
$163,080
|
Collisson, Eric
|
UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
|
|
A mouse model for human gastrointestinal stromal tumor
|
5R01CA102774-08
|
$390,130
|
$390,130
|
BESMER, PETER
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
A Multi-Purpose Nanovehicle for Targeted Boron Neutron Capture Cancer Therapy & I
|
1R15CA156393-01A1
|
$352,700
|
$352,700
|
Webb, Andrew
|
WELLESLEY COLLEGE
|
|
A Multi-State Study of Cancer Treatment and Outcomes Among American Indians
|
5R01CA125231-06
|
$374,097
|
$89,783
|
RAMSEY, SCOTT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
A Multidisciplinary and Translational Approach to Hepatobiliary Malignancy
|
5K24CA139570-03
|
$186,940
|
$186,940
|
Nelson, David
|
UNIVERSITY OF FLORIDA
|
|
A Needle Guidance System for Hepatic Tumor Ablation That Fuses Real-Time Ultrasou
|
2R44CA143234-02A1
|
$652,814
|
$652,814
|
Razzaque, Sharif
|
INNEROPTIC TECHNOLOGY, INC.
|
|
A New Method for Improved Targeting in Image-guided Abdominal Interventions
|
5R01CA138586-03
|
$359,276
|
$359,276
|
Hata, Nobuhiko
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A novel agent suppresses colitis and colon cancer
|
1R03CA158669-01A1
|
$78,500
|
$78,500
|
Ouyang, Nengtai
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
A novel combination therapy for the treatment of Pancreatic adenocarcinoma
|
5R03CA149857-02
|
$74,250
|
$74,250
|
HOLLINGSWORTH, MICHAEL
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
A novel diagnostic biomarker for hepatocellular carcinoma and cholangiocarcinoma
|
1R43CA165314-01A1
|
$292,459
|
$292,459
|
Lu, Xuanyong
|
IMCARE BIOTECH
|
|
A novel murine model for metastatic islet cell pancreas cancer
|
1R21CA164795-01
|
$219,599
|
$219,599
|
GROSS, KENNETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
A Prospective Study of Colorectal Cancer: One-Carbon Metabolism and Inflammation
|
5R01CA120523-05
|
$488,576
|
$488,576
|
ULRICH, CORNELIA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
A Randomized Trial of Hep B Screening and Vaccination in High Risk Vietnamese
|
5R01CA129763-06
|
$477,672
|
$477,672
|
MA, GRACE
|
TEMPLE UNIVERSITY
|
|
A Risk Prediction Model for Colorectal Cancer Screening
|
5R01CA131197-05
|
$430,622
|
$430,622
|
SCHROY, PAUL
|
BOSTON MEDICAL CENTER
|
|
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
|
1R41CA174031-01
|
$266,641
|
$266,641
|
Jones, Barry
|
ARISAPH PHARMACEUTICALS, INC.
|
|
A Study of the Prevalence of Esophageal Squamous Dysplasia in Western Kenya: the STEP Study
|
ZIA CP000185-10575
|
$39,311
|
$39,311
|
Dawsey, Sanford
|
DCEG (NCI)
|
|
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response
|
5U01CA084244-14
|
$759,738
|
$151,948
|
BALMAIN, ALLAN
|
UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
|
|
A Tumor Suppressor Function for the c-Fes Tyrosine Kinase in Colon Cancer
|
5R01CA123756-05
|
$252,084
|
$252,084
|
SMITHGALL, THOMAS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
AANCART: The National Center for Reducing Asian American Cancer Health Disparitie
|
3U54CA153499-03S1
|
$33,534
|
$8,384
|
CHEN, MOON
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
AANCART: The National Center for Reducing Asian American Cancer Health Disparitie
|
3U54CA153499-03S2
|
$50,001
|
$12,500
|
CHEN, MOON
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
AANCART: The National Center for Reducing Asian American Cancer Health Disparitie
|
3U54CA153499-03S3
|
$119,786
|
$29,947
|
CHEN, MOON
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
AANCART: The National Center for Reducing Asian American Cancer Health Disparitie
|
5U54CA153499-03
|
$968,834
|
$242,209
|
CHEN, MOON
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196-03152
|
$1,258,475
|
$62,924
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
Aberrant DNA Methylation of MicroRNA Genes in Hepatocellular Carcinoma (HCC)
|
5R03CA156629-02
|
$80,000
|
$80,000
|
Shen, Jing
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Aberrant Glycosylation Signature in Pancreatic Cancer
|
5R21CA149772-02
|
$208,128
|
$208,128
|
Pan, Sheng
|
UNIVERSITY OF WASHINGTON
|
|
Aberrantly secreted glycoproteins as markers of liver cancer
|
1U01CA168856-01
|
$293,548
|
$293,548
|
Mehta, Anand
|
Drexel University
|
|
Academic-Industrial Partnership to Develop & Test Esophageal Cancer Imaging Tools
|
5R01CA140257-03
|
$576,620
|
$576,620
|
RICHARDS-KORTUM, REBECCA
|
RICE UNIVERSITY
|
|
Accurate, High Resolution 3D Dosimetry
|
5R01CA100835-09
|
$278,725
|
$139,363
|
OLDHAM, MARK
|
DUKE UNIVERSITY
|
|
ACOSOG Community Clinical Oncology Program (CCOP) Research Base
|
5U10CA149950-02
|
$1,474,780
|
$383,443
|
Sloan, Jeff
|
MAYO CLINIC
|
|
ACOSOG Competing Renewal
|
7U10CA076001-16
|
$2,940,780
|
$970,457
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
ACTIVIN SIGNALING AND REGULATION IN THE COLON
|
5R01CA141057-03
|
$276,251
|
$276,251
|
JUNG, BARBARA
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
ADAM17 in pancreatic cancer and pancreatitis
|
7R01CA159222-02
|
$390,135
|
$390,135
|
CRAWFORD, HOWARD
|
MAYO CLINIC JACKSONVILLE
|
|
Adding Hispanics to Ongoing GWAS in Colorectal Cancer
|
5R01CA155101-02
|
$1,116,233
|
$1,116,233
|
Figueiredo, Jane
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Adoption and Retooling of GEM model for Pancreatic Cancer
|
ZIABC011463
|
$148,216
|
$148,216
|
Van Dyke, Terry
|
CCR (NCI)
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIABC010984
|
$1,556,987
|
$155,699
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Advanced Development of a Multiplexed SERS-based Biomarker Detection Platform: A
|
5R33CA155586-02
|
$334,432
|
$334,432
|
Porter, Marc
|
UNIVERSITY OF UTAH
|
|
Advanced glycation end products and colorectal cancer risk in women
|
5R03CA156626-02
|
$80,193
|
$80,193
|
JIAO, LI
|
BAYLOR COLLEGE OF MEDICINE
|
Total relevant funding to Digestive Diseases for this search: $459,809,564
|